← Back to all trials
Recruiting
NCT06807281
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Conditions: Atopic Dermatitis
Sex: All
Ages: 2 Years – 11 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 500
Sponsor: Pfizer
Location: Cahaba Dermatology & Skin Health Center Birmingham Alabama
Summary
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Eligibility Criteria
Inclusion Criteria for the Extension Cohort:
1\. Participants who have completed the treatment phase of the qualifying parent study (age 2 to \
Source: ClinicalTrials.gov (NCT06807281). StuddyBuddy aggregates publicly available trial information.
